- FDA finally approves Reata’s rare genetic disease drugTerminal News
- FDA expands pathway for rare disease treatments with new approvalThe Wall Street Journal
- RETA Stock Soars as FDA Approves Reata Phama’s Neurological Drug | Investor’s Business DailyInvestor’s Business Daily
- Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxiabusiness thread
- Why Reata Pharma (RETA) Stocks Are Soaring Today – Reata Pharmaceuticals (NASDAQ:RETA)Gasoline
- See full coverage on Google News